Physician profile
Kimberly A Brown
NPI 1508934035
$732,576.43
in general payments reported to CMS, 2019-2025
18 companies · $157K in 2025
The $157K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $65K · 2021: $69K · 2022: $131K · 2023: $130K · 2024: $134K · 2025: $157K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $260K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $78K · Consulting Fee: $55K · Travel and Lodging: $21K · Food and Beverage: $6,183 · Honoraria: $1,240 · Education: $52.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $259,871.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $78,465.00 |
| Consulting Fee | $54,790.00 |
| Travel and Lodging | $20,744.92 |
| Food and Beverage | $6,183.24 |
| Honoraria | $1,240.00 |
| Education | $52.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $324,432.46 | 2019-2025 | Epclusa, Livdelzi, Vemlidy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120,561.54 | 2020-2025 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $99,514.02 | 2020-2025 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $86,244.26 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $53,599.56 | 2024-2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $37,691.13 | 2024-2025 | Iqirvo |
| Glaxosmithkline, LLC. | $4,000.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $1,900.00 | 2023 | |
| Abbvie INC. | $1,742.58 | 2021-2022 | |
| Novo Nordisk As | $866.00 | 2019 | |
| Bausch Health US, LLC | $800.00 | 2025 | |
| Astrazeneca Uk Limited | $700.00 | 2023 | |
| Novo Nordisk INC | $285.83 | 2021-2024 | |
| Exact Sciences Corporation | $126.31 | 2024 | |
| Boston Scientific Corporation | $66.79 | 2023-2025 | Varithena Administration Pack |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.95 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.